On Monday, Aquestive Therapeutics Inc (NASDAQ: AQST) was -7.62% drop from the session before settling in for the closing price of $6.04. A 52-week range for AQST has been $2.12 – $7.55.
Annual sales at Healthcare sector company grew by 27.90% over the past five years. When this article was written, the company’s average yearly earnings per share was at -22.35%. With a float of $115.51 million, this company’s outstanding shares have now reached $121.66 million.
Aquestive Therapeutics Inc (AQST) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aquestive Therapeutics Inc stocks. The insider ownership of Aquestive Therapeutics Inc is 5.32%, while institutional ownership is 40.60%. The most recent insider transaction that took place on Oct 15 ’25, was worth 473,701. In this transaction Chief Operating Officer of this company sold 67,575 shares at a rate of $7.01, taking the stock ownership to the 240,771 shares. Before that another transaction happened on Oct 15 ’25, when Company’s Chief Medical Officer sold 20,272 for $7.00, making the entire transaction worth $141,904. This insider now owns 282,475 shares in total.
Aquestive Therapeutics Inc (AQST) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.16 earnings per share (EPS) during the time that was less than consensus figure (set at -0.13) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.68% during the next five years compared to 27.90% growth over the previous five years of trading.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
You can see what Aquestive Therapeutics Inc (AQST) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Aquestive Therapeutics Inc (NASDAQ: AQST) saw its 5-day average volume 3.34 million, a positive change from its year-to-date volume of 1.98 million. As of the previous 9 days, the stock’s Stochastic %D was 17.52%.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 55.43%, which indicates a significant increase from 8.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.43 in the past 14 days, which was higher than the 0.31 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.92, while its 200-day Moving Average is $3.89. Nevertheless, the first resistance level for the watch stands at $6.02 in the near term. At $6.46, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.75. If the price goes on to break the first support level at $5.29, it is likely to go to the next support level at $5.00. Assuming the price breaks the second support level, the third support level stands at $4.56.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
There are 122,003K outstanding shares of the company, which has a market capitalization of 680.78 million. As of now, sales total 57,560 K while income totals -44,140 K. Its latest quarter income was 10,000 K while its last quarter net income were -13,550 K.
